Cartesian Therapeutics (RNAC) Other Operating Expenses (2023 - 2025)

Cartesian Therapeutics (RNAC) has 3 years of Other Operating Expenses data on file, last reported at $56.7 million in Q4 2025.

• Quarterly Other Operating Expenses rose 648.12% year-over-year to $56.7 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $56.7 million (up 648.12% YoY) and the FY2025 annual result came in at $56.7 million, up 648.12% from the prior year.
• Other Operating Expenses improved to $56.7 million in Q4 2025 per RNAC's latest filing, from $7.6 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $56.7 million in Q4 2025 and bottomed at $710000.0 in Q4 2023.
• The 3-year median for Other Operating Expenses is $7.6 million (2024), against an average of $21.7 million.
• The widest annual swing landed in 2024, when Other Operating Expenses jumped 967.46%; it then soared 648.12% in 2025.
• Tracing RNAC's Other Operating Expenses over 3 years: stood at $710000.0 in 2023, then jumped by 967.46% to $7.6 million in 2024, then soared by 648.12% to $56.7 million in 2025.
• Per Business Quant, the three latest RNAC Other Operating Expenses figures stand at $56.7 million (Q4 2025), $7.6 million (Q4 2024), and $710000.0 (Q4 2023).

Peer Comparison